🇺🇸 FDA
Pipeline program

Target CD7 CAR-T cells

GUT03

Phase 1 mab terminated

Quick answer

Target CD7 CAR-T cells for T-cell Acute Lymphoblastic Leukemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
T-cell Acute Lymphoblastic Leukemia
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials